JP2012521997A - 眼内徐放型ドラッグ送達システムおよび眼症状を処置する方法 - Google Patents

眼内徐放型ドラッグ送達システムおよび眼症状を処置する方法 Download PDF

Info

Publication number
JP2012521997A
JP2012521997A JP2012502224A JP2012502224A JP2012521997A JP 2012521997 A JP2012521997 A JP 2012521997A JP 2012502224 A JP2012502224 A JP 2012502224A JP 2012502224 A JP2012502224 A JP 2012502224A JP 2012521997 A JP2012521997 A JP 2012521997A
Authority
JP
Japan
Prior art keywords
compound
weight percent
microspheres
implant
latanoprost
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012502224A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012521997A5 (https=
Inventor
マイケル アール ロビンソン
ジェイムズ エイ バーク
フイ リウ
ワーナー シー オリーラ
ロン ティー スパーダ
スコット ウィットカップ
アラザル エヌ ゲブレメスケル
パトリック エム ヒューズ
クン シュー
マリアン エム ドゥー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of JP2012521997A publication Critical patent/JP2012521997A/ja
Publication of JP2012521997A5 publication Critical patent/JP2012521997A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012502224A 2009-03-25 2010-03-25 眼内徐放型ドラッグ送達システムおよび眼症状を処置する方法 Pending JP2012521997A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/411,250 US20100247606A1 (en) 2009-03-25 2009-03-25 Intraocular sustained release drug delivery systems and methods for treating ocular conditions
US12/411,250 2009-03-25
PCT/US2010/028584 WO2010111449A1 (en) 2009-03-25 2010-03-25 Intraocular sustained release drug delivery systems and methods for treating ocular conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014183177A Division JP2015007117A (ja) 2009-03-25 2014-09-09 眼内徐放型ドラッグ送達システムおよび眼症状を処置する方法

Publications (2)

Publication Number Publication Date
JP2012521997A true JP2012521997A (ja) 2012-09-20
JP2012521997A5 JP2012521997A5 (https=) 2013-05-16

Family

ID=42326990

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012502224A Pending JP2012521997A (ja) 2009-03-25 2010-03-25 眼内徐放型ドラッグ送達システムおよび眼症状を処置する方法
JP2014183177A Pending JP2015007117A (ja) 2009-03-25 2014-09-09 眼内徐放型ドラッグ送達システムおよび眼症状を処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014183177A Pending JP2015007117A (ja) 2009-03-25 2014-09-09 眼内徐放型ドラッグ送達システムおよび眼症状を処置する方法

Country Status (13)

Country Link
US (1) US20100247606A1 (https=)
EP (1) EP2411013B1 (https=)
JP (2) JP2012521997A (https=)
KR (4) KR20120006998A (https=)
CN (1) CN102497865A (https=)
AU (3) AU2010229891A1 (https=)
BR (1) BRPI1012324A2 (https=)
CA (1) CA2756065A1 (https=)
IL (1) IL215205A0 (https=)
MX (1) MX2011009901A (https=)
NZ (1) NZ595294A (https=)
RU (2) RU2532333C2 (https=)
WO (1) WO2010111449A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014530177A (ja) * 2011-09-16 2014-11-17 フオベア・フアルマシユテイカル アニリン誘導体、それらの調製およびそれらの治療適用
JP2016515618A (ja) * 2013-04-01 2016-05-30 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 持続的眼内放出のためのマイクロスフェア薬剤送達システム
JP2016520561A (ja) * 2013-04-12 2016-07-14 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 脂肪減少のためのビマトプロスト、ビマトプロスト類似体、プロスタミド及びプロスタグランジンの持続放出
JP2018528169A (ja) * 2015-08-19 2018-09-27 ジェニヴィジョン インク． 眼科用薬物の定量的な眼窩周囲への適用

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20090148527A1 (en) * 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US7947732B2 (en) * 2007-07-13 2011-05-24 Allergan, Inc. Therapeutic substituted chlorocyclopentanols
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
JP5591226B2 (ja) 2008-05-12 2014-09-17 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション 眼内薬物送達装置および関連する方法
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US20100104654A1 (en) 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
CA3186189A1 (en) 2009-05-18 2010-11-25 Dose Medical Corporation Drug eluting ocular implant
EP3085358B1 (en) * 2010-01-22 2017-11-01 Allergan, Inc. Intracameral sustained release therapeutic agent implants
US10413506B2 (en) 2010-04-03 2019-09-17 Praful Doshi Medical devices including medicaments and methods of making and using same including enhancing comfort, enhancing drug penetration, and treatment of myopia
JP2013524275A (ja) 2010-04-03 2013-06-17 ドシ，プラフル 薬剤を含む医療機器、その製造方法とその使用方法
US20120022137A1 (en) * 2010-07-21 2012-01-26 Rivers Hongwen M METHOD OF CONTROLLING INITIAL DRUG RELEASE OF siRNA FROM SUSTAINED-RELEASE IMPLANTS
US10272040B2 (en) 2010-08-12 2019-04-30 Nanyang Technological University Liposomal formulation for ocular drug delivery
CN103167875A (zh) * 2010-08-17 2013-06-19 阿勒根公司 用于治疗角膜浑浊的ep2或ep4激动剂
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
US20120276186A1 (en) 2011-04-29 2012-11-01 Ghebremeskel Alazar N Sustained release latanoprost implant
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
US20130035338A1 (en) * 2011-08-05 2013-02-07 Gordon Tang Eyelid treatment
EP2567689A1 (en) * 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
EP2623490A1 (en) * 2012-02-03 2013-08-07 Fovea Pharmaceuticals 2-(3-aminophenoxy)-acetic acid derivatives as EP2 receptor agonists for use in treatment of glaucoma
EP2570402A1 (en) * 2011-09-16 2013-03-20 Fovea Pharmaceuticals Bi-aryl derivatives, their preparation and their therapeutic application
TWI560172B (en) * 2011-11-02 2016-12-01 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
EP2950782B1 (en) 2013-01-31 2017-12-27 Icon Bioscience, Inc. Sustained release formulations for the treatment of intraocular pressure or glaucoma
CN104055695B (zh) * 2013-03-22 2016-12-28 深圳市绿蛙生物科技有限公司 中药型快干消毒护手霜及其制备方法
CN105682645B (zh) 2013-10-31 2019-09-06 阿勒根公司 含前列腺酰胺的眼内植入物及其使用方法
MX2016007345A (es) * 2013-12-06 2016-12-09 Envisia Therapeutics Inc Implante intracameral para el tratamiento de una condicion ocular.
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
US9981938B2 (en) 2014-05-12 2018-05-29 Allergan, Inc. Quaternary ammonium alkyl esters as stable prodrugs
EP3677229A1 (en) 2014-05-29 2020-07-08 Glaukos Corporation Implants with controlled drug delivery features
CN105266952A (zh) * 2014-07-09 2016-01-27 首都医科大学附属北京同仁医院 一种抗青光眼手术中所用防术后结膜粘连的器材
CN109481447A (zh) * 2014-09-06 2019-03-19 整体生物系统有限责任公司 用于在眼中实现持续药物释放的方法和生物相容性组合物
EP3233067B1 (en) * 2014-12-18 2019-11-06 DSM IP Assets B.V. Drug delivery system for delivery of acid sensitive drugs
US10010502B2 (en) 2015-05-19 2018-07-03 Amorphex Therapeutics Llc Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation
KR102643821B1 (ko) * 2015-06-06 2024-03-07 클라우드브레이크 테라퓨틱스, 엘엘씨 익상편을 치료하기 위한 조성물 및 방법
EP3324944A4 (en) * 2015-07-23 2019-04-03 Aerie Pharmaceuticals, Inc. INTRAVITREAL AGGREGATION SYSTEMS FOR THE TREATMENT OF EYE DISEASE
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
US11458041B2 (en) 2015-10-08 2022-10-04 Ocular Therapeutix, Inc. Punctal plug and bioadhesives
GB201522441D0 (en) 2015-12-18 2016-02-03 Midatech Pharma Wales Ltd Sustained release cyclosporine-loaded microparticles
EP3442479B1 (en) 2016-04-20 2026-03-04 Glaukos Corporation Bioresorbable ocular drug delivery device
KR102657707B1 (ko) 2016-06-02 2024-04-15 에이디에스 테라퓨틱스 엘엘씨 녹내장 수술 성공을 개선하기 위해 닌테다닙을 사용하는 조성물 및 방법
DK3515406T3 (da) * 2016-09-23 2024-10-14 Incept Llc Intrakamerale depoter til lægemiddeladministration
US20200206137A1 (en) * 2017-07-17 2020-07-02 Wolfcreek Biotech Pte Ltd Microparticle formulations for delivery of active agents
RU2685499C1 (ru) * 2018-07-19 2019-04-18 федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ лечения прогрессирующей миопии у детей с выявленным привычно-избыточным напряжением аккомодации
WO2020047141A1 (en) * 2018-08-30 2020-03-05 Liu Yunxiang Ophthalmic injectable formulation preparing and oculopathy treating and preventing
PL427837A1 (pl) * 2018-11-22 2020-06-01 Gbj Pharma Spółka Z Ograniczoną Odpowiedzialnością Systemy do ciągłego obwodowego podawania latanoprostu dla obniżania ciśnienia śródgałkowego
EP3920986A4 (en) * 2019-02-08 2022-10-26 Ohio State Innovation Foundation ANTIOXIDANT-RELEASING VITREOUS SUBSTITUTES AND THEIR USES
CA3166738A1 (en) 2020-02-06 2021-08-12 Charles D. Blizzard Travoprost compositions and methods for treating ocular diseases
EP3884929B1 (en) 2020-03-25 2023-06-14 Ocular Therapeutix, Inc. Ocular implant containing a tyrosine kinase inhibitor
WO2021222117A1 (en) 2020-04-27 2021-11-04 Ocular Therapeutix, Inc. Methods of treating allergic conjunctivitis
EP4149400B1 (en) * 2020-05-15 2026-04-22 Georgia Tech Research Corporation Methods and compositions for reducing intraocular pressure
US12064376B2 (en) * 2020-06-03 2024-08-20 Glaukos Corporation Rho kinase inhibitor releasing implants and related methods of use
WO2022170112A1 (en) * 2021-02-05 2022-08-11 Jenivision Inc. Compositions and methods for periorbital administration of ep2 receptor agonists
CN113133431A (zh) * 2021-02-25 2021-07-20 中南大学 慢性高眼压合并长眼轴动物模型的建立方法、模型及应用
CN120897764A (zh) 2023-04-11 2025-11-04 视尔普斯眼科公司 包含阿西替尼多晶型物iv的眼部植入物
WO2024243081A1 (en) * 2023-05-19 2024-11-28 The Trustees Of Columbia University In The City Of New York Treating elevated intraocular pressure with nicotinamide
US12605394B2 (en) 2024-07-25 2026-04-21 Visionary Assets, Llc Compositions containing cannabinoid nanoparticles

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10510293A (ja) * 1995-04-18 1998-10-06 ガリン，マイルズ，エー． 前房における縮瞳および散瞳薬のコントロールドリリース
US20060246145A1 (en) * 2004-04-30 2006-11-02 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid containing microparticles
JP2007518804A (ja) * 2004-01-20 2007-07-12 アラーガン、インコーポレイテッド トリアムシノロンアセトニドおよびヒアルロン酸を好ましく含有する眼局所治療用組成物
JP2007535537A (ja) * 2004-04-30 2007-12-06 アラーガン、インコーポレイテッド プロスタミド含有生分解性眼内インプラント
WO2008070402A2 (en) * 2006-12-01 2008-06-12 Allergan, Inc. Intraocular drug delivery systems
WO2008091818A1 (en) * 2007-01-25 2008-07-31 Allergan, Inc. Substituted arylcyclopentenes as therapeutic agents
WO2008134644A1 (en) * 2007-04-30 2008-11-06 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
JP2009511632A (ja) * 2005-10-18 2009-03-19 アラーガン、インコーポレイテッド 後区組織に選択的に浸透するグルココルチコイド誘導体を用いた眼治療

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT252264B (de) * 1965-03-17 1967-02-10 Etapharm Chem Pharm Lab Ges M Verfahren zur Herstellung eines reinen hochviskosen Hyaluronsäurepräparates
US3749776A (en) * 1970-08-28 1973-07-31 Allergan Pharma Method for blocking prostaglandin activity
US4403353A (en) * 1981-06-25 1983-09-13 Tennant Jerald L Anterior chamber implant lens
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US5166331A (en) * 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
US6309669B1 (en) * 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US5585401A (en) * 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
US5972326A (en) * 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
US7867186B2 (en) * 2002-04-08 2011-01-11 Glaukos Corporation Devices and methods for treatment of ocular disorders
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
WO2003092665A2 (en) * 2002-05-02 2003-11-13 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
ATE418323T1 (de) * 2002-11-06 2009-01-15 Alza Corp Depot-formulierungen mit verzögerter freisetzung
US20040193095A1 (en) * 2003-03-29 2004-09-30 Shadduck John H. Implants for treating ocular hypertension, methods of use and methods of fabrication
EP1718274A2 (en) * 2004-01-26 2006-11-08 Control Delivery Systems, Inc. Controlled and sustained delivery of nucleic acid-based therapeutic agents
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US20050244471A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US7993634B2 (en) * 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8147865B2 (en) * 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
CA2599425C (en) * 2005-03-10 2013-04-30 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US7585895B2 (en) * 2005-12-06 2009-09-08 Allergan, Inc. Therapeutic substituted cyclopentanes
US7427685B2 (en) * 2005-12-06 2008-09-23 Allergan, Inc. Therapeutic substituted cyclopentanes
WO2007070866A2 (en) * 2005-12-16 2007-06-21 Alcon, Inc. Control of intraocular pressure using alk5 modulation agents
WO2007084582A2 (en) * 2006-01-17 2007-07-26 Forsight Labs, Llc Drug delivery treatment device
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US9039761B2 (en) * 2006-08-04 2015-05-26 Allergan, Inc. Ocular implant delivery assemblies with distal caps
SG174031A1 (en) * 2006-08-07 2011-09-29 Bausch & Lomb Treating infections and sequelae thereof with combined dissociated' glucocorticoid receptor agonists and anti-infective agents
US8846073B2 (en) * 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
US7589213B2 (en) * 2007-04-27 2009-09-15 Old David W Therapeutic substituted lactams
US7947732B2 (en) * 2007-07-13 2011-05-24 Allergan, Inc. Therapeutic substituted chlorocyclopentanols
IL186598A0 (en) * 2007-10-11 2008-11-03 Mohammad Abdulrazik Composition and method for the treatment or prevention of glaucoma and ocular hypertension
UA99840C2 (ru) * 2007-11-09 2012-10-10 Аллерган, Инк. Замещенные циклопентаны, которые имеют простагландиновую активность
CA2721749A1 (en) * 2008-04-16 2009-10-22 Allergan, Inc. Combination therapy for glaucoma
WO2009143288A1 (en) * 2008-05-20 2009-11-26 Yale University Biodegradable sustained-release polymeric microparticulates comprising a hydrophobic drug and determined for ophthalmic use
US20100104654A1 (en) * 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
EP3085358B1 (en) * 2010-01-22 2017-11-01 Allergan, Inc. Intracameral sustained release therapeutic agent implants

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10510293A (ja) * 1995-04-18 1998-10-06 ガリン，マイルズ，エー． 前房における縮瞳および散瞳薬のコントロールドリリース
JP2007518804A (ja) * 2004-01-20 2007-07-12 アラーガン、インコーポレイテッド トリアムシノロンアセトニドおよびヒアルロン酸を好ましく含有する眼局所治療用組成物
US20060246145A1 (en) * 2004-04-30 2006-11-02 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid containing microparticles
JP2007535537A (ja) * 2004-04-30 2007-12-06 アラーガン、インコーポレイテッド プロスタミド含有生分解性眼内インプラント
JP2009511632A (ja) * 2005-10-18 2009-03-19 アラーガン、インコーポレイテッド 後区組織に選択的に浸透するグルココルチコイド誘導体を用いた眼治療
WO2008070402A2 (en) * 2006-12-01 2008-06-12 Allergan, Inc. Intraocular drug delivery systems
WO2008091818A1 (en) * 2007-01-25 2008-07-31 Allergan, Inc. Substituted arylcyclopentenes as therapeutic agents
WO2008134644A1 (en) * 2007-04-30 2008-11-06 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014530177A (ja) * 2011-09-16 2014-11-17 フオベア・フアルマシユテイカル アニリン誘導体、それらの調製およびそれらの治療適用
JP2016515618A (ja) * 2013-04-01 2016-05-30 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 持続的眼内放出のためのマイクロスフェア薬剤送達システム
JP2016520561A (ja) * 2013-04-12 2016-07-14 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 脂肪減少のためのビマトプロスト、ビマトプロスト類似体、プロスタミド及びプロスタグランジンの持続放出
US10682361B2 (en) 2013-04-12 2020-06-16 Allergan, Inc. Sustained release bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction
JP2018528169A (ja) * 2015-08-19 2018-09-27 ジェニヴィジョン インク． 眼科用薬物の定量的な眼窩周囲への適用

Also Published As

Publication number Publication date
AU2016231616A1 (en) 2016-10-20
KR20160120800A (ko) 2016-10-18
RU2532333C2 (ru) 2014-11-10
RU2664686C2 (ru) 2018-08-21
BRPI1012324A2 (pt) 2016-03-15
EP2411013A1 (en) 2012-02-01
MX2011009901A (es) 2011-11-18
US20100247606A1 (en) 2010-09-30
AU2010229891A1 (en) 2011-10-20
KR20180108883A (ko) 2018-10-04
CA2756065A1 (en) 2010-09-30
EP2411013B1 (en) 2020-08-19
CN102497865A (zh) 2012-06-13
RU2014133501A (ru) 2016-03-10
JP2015007117A (ja) 2015-01-15
KR20120006998A (ko) 2012-01-19
RU2011140433A (ru) 2013-04-27
KR20170064556A (ko) 2017-06-09
NZ595294A (en) 2013-11-29
WO2010111449A1 (en) 2010-09-30
AU2018211329A1 (en) 2018-08-23
IL215205A0 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
RU2532333C2 (ru) Внутриглазные системы доставки лекарственного средства с замедленным высвобождением и способы лечения глазных заболеваний
JP5580832B2 (ja) 生分解性α−２アゴニストポリマー性インプラントおよびその治療用途
RU2440102C2 (ru) Системы доставки лекарственного средства внутрь глаза
JP6570513B2 (ja) 持続的眼内放出のためのマイクロスフェア薬剤送達システム
JP6132964B2 (ja) 萎縮性加齢性黄斑変性の処置方法
JP6416154B2 (ja) 眼房内ビマトプロスト注入物による眼圧低下
JP5696121B2 (ja) α−２アドレナリン受容体アゴニスト含有生分解性眼内インプラント
JP2007535367A (ja) エストラジオール誘導体またはエストラトポン誘導体を含有する徐放性眼内インプラント、ならびに関連する製造法
AU2014202336A1 (en) Intraocular drug delivery systems
HK1165708B (en) Intracameral sustained release drug delivery systems
HK1165708A (en) Intracameral sustained release drug delivery systems

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140217

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140609

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141104